沙利度胺联合GP方案治疗晚期非小细胞肺癌的疗效及对血清VEGF、bFGF、TNF-α和生活质量的影响

发布时间：2018-09-17 14:03

【摘要】：目的探讨沙利度胺(TGP)联合顺铂和吉西他滨(GP)方案治疗晚期非小细胞肺癌(NSCLC)的疗效及对血清血管内皮生长因子(VEGF)、碱性成纤维细胞生长因子(b FGF)和肿瘤坏死因子(TNF)-α及生活质量的影响。方法选择晚期NSCLC患者80例,按照乱数表法分为研究组和对照组均40例。对照组采用GP治疗方案,研究组在对照组的基础上联用TGP治疗,两组均治疗42 d。两组分别于治疗前、治疗后测定血清VEGF、b FGF和TNF-α水平,并应用欧洲癌症研究与治疗组织(EORTC)生活质量量表(QLQ-C30)评定患者的生活质量。结果两组有效率无显著差异(P0.05)。治疗后研究组血清VEGF、b FGF和TNF-α水平较治疗前显著降低,且显著低于对照组(P0.05),对照组无明显变化(P0.05)。治疗后,两组恶心呕吐、食欲、便秘评分较治疗前显著升高,气促评分较治疗前显著降低(P0.05),对照组整体生活质量评分显著低于治疗前(P0.05)。治疗后研究组整体生活质量、食欲、便秘评分显著高于对照组,恶心呕吐、气促评分显著低于对照组(P0.05)。结论 TGP联合GP方案治疗晚期NSCLC的疗效与单独GP方案相当,但患者血清VEGF、b FGF和TNF-α水平下降更明显,生活质量得到更好的改善。
[Abstract]:Objective to evaluate the efficacy of thalidomide (TGP) combined with cisplatin and gemcitabine (GP) in the treatment of advanced non-small cell lung cancer (NSCLC) with (NSCLC), and to evaluate the efficacy of thalidomide (TGP) combined with cisplatin and gemcitabine (GP) in the treatment of advanced non-small cell lung cancer (NSCLC). The impact of quality of life Methods 80 patients with advanced NSCLC were divided into study group and control group. The control group was treated with GP regimen, the study group was treated with TGP on the basis of the control group, both groups were treated for 42 days. The serum levels of VEGF,b FGF and TNF- 伪 were measured before and after treatment, and the quality of life (QOL) was evaluated by (EORTC) quality of life (QLQ-C30) of European Cancer Research and treatment Organization. Results there was no significant difference in the effective rate between the two groups (P0.05). After treatment, the levels of serum VEGF,b FGF and TNF- 伪 in the study group were significantly lower than those in the control group (P0.05), but there were no significant changes in the control group (P0.05). After treatment, the scores of nausea and vomiting, appetite and constipation in the two groups were significantly higher than those before treatment, and the score of shortness of breath was significantly lower than that before treatment (P0.05), while the overall quality of life score in the control group was significantly lower than that before treatment (P0.05). After treatment, the overall quality of life, appetite, constipation score in the study group was significantly higher than that in the control group, nausea and vomiting score was significantly lower than that in the control group (P0.05). Conclusion the efficacy of TGP combined with GP regimen in the treatment of advanced NSCLC is similar to that of GP alone, but the levels of serum VEGF,b FGF and TNF- 伪 decrease more significantly, and the quality of life is improved better.
【作者单位】：丹阳市人民医院肿瘤科;
【分类号】：R734.2

【相似文献】